Ciprofloxacin/hydrocortisone otic solution

Drug Profile

Ciprofloxacin/hydrocortisone otic solution

Alternative Names: Cipro HC Otic Suspension; Ciproxin HC

Latest Information Update: 27 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Anti-inflammatories; Antiallergics; Antibacterials; Fluoroquinolones; Glucocorticoids
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Otitis externa

Most Recent Events

  • 26 Aug 2010 Alcon has been acquired by Novartis
  • 28 Jun 2001 ALZA Corporation has been acquired by Johnson & Johnson
  • 14 Nov 2000 ALZA has entered an agreement with Bayer to copromote Cipro® in the US market
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top